Sequencing method for CAR T cell therapy

A method of treating a patient for cancer, the method comprising

• i) administering to the patient at least one dose of a chimeric antigen receptor T cell (CAR T cell) composition comprising CAR T cells comprising a chimeric antigen receptor (CAR) directed to a targeting moiety;
• and
• ii) administering to the patient a compound, or a pharmaceutically acceptable salt thereof, wherein the compound comprises a small molecule ligand linked to the targeting moiety by a linker, wherein the small molecule ligand is folate and wherein the targeting moiety is fluorescein, or a pharmaceutically acceptable salt thereof, fluorescein isothiocyanate (FITC), or NHS-fluorescein, and wherein the compound, or the pharmaceutically acceptable salt thereof, is administered in at least a first dose escalation sequence and a second dose escalation sequence, wherein a full dose of the compound, or the pharmaceutically acceptable salt thereof, is 10 μg/kg to 50 μg/kg of the compound, or the pharmaceutically acceptable salt thereof;
• wherein the first dose escalation sequence for the compound, or the pharmaceutically acceptable salt thereof, comprises administering 3 separate escalating doses up to the full dose of the compound on three separate days in a first two-week cycle;
• and
• wherein the second dose escalation sequence for the compound, or the pharmaceutically acceptable salt thereof, comprises administering 3 separate escalating doses up to the full dose of the compound on three separate days in a second two-week cycle,
• whereupon the patient is treated for cancer, and wherein the patient is a human.